CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 192 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $792,582 | -40.7% | 67,800 | -31.8% | 0.01% | -38.5% |
| Q2 2023 | $1,335,681 | -18.9% | 99,381 | 0.0% | 0.01% | -18.8% |
| Q1 2023 | $1,647,737 | -10.9% | 99,381 | 0.0% | 0.02% | 0.0% |
| Q4 2022 | $1,848,487 | -35.6% | 99,381 | -55.6% | 0.02% | -27.3% |
| Q3 2022 | $2,872,000 | +70.9% | 223,812 | -6.7% | 0.02% | +83.3% |
| Q2 2022 | $1,681,000 | -24.3% | 239,795 | -10.5% | 0.01% | -7.7% |
| Q1 2022 | $2,222,000 | +83.6% | 268,012 | +50.0% | 0.01% | +85.7% |
| Q4 2021 | $1,210,000 | +27.8% | 178,700 | 0.0% | 0.01% | -12.5% |
| Q3 2021 | $947,000 | +38.7% | 178,700 | +50.4% | 0.01% | +33.3% |
| Q2 2021 | $683,000 | +187.0% | 118,800 | +48.5% | 0.01% | +100.0% |
| Q3 2020 | $238,000 | -35.7% | 80,000 | 0.0% | 0.00% | -25.0% |
| Q2 2020 | $370,000 | +26.3% | 80,000 | +45.2% | 0.00% | +33.3% |
| Q3 2019 | $293,000 | – | 55,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |